Online inquiry

IVTScrip™ mRNA-Anti-pagA, ETI-204(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6989MR)

This product GTTS-WQ6989MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets pagA gene. The antibody can be applied in Anthrax research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq WP_000746486.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 45025512
UniProt ID P13423
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-pagA, ETI-204(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ6989MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3127MR IVTScrip™ mRNA-Anti-B4GALNT1, APN311(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA APN311
GTTS-WQ13353MR IVTScrip™ mRNA-Anti-PDCD1, PF-06801591(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PF-06801591
GTTS-WQ3862MR IVTScrip™ mRNA-Anti-IL6R, BCD-089(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BCD-089
GTTS-WQ6251MR IVTScrip™ mRNA-Anti-HA, CR-6261(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CR-6261
GTTS-WQ12497MR IVTScrip™ mRNA-Anti-MUC5AC, NOE-102(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA NOE-102
GTTS-WQ12809MR IVTScrip™ mRNA-Anti-MASP2, OMS721(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA OMS721
GTTS-WQ14832MR IVTScrip™ mRNA-Anti-CD70, SGN-75(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA SGN-75
GTTS-WQ12508MR IVTScrip™ mRNA-Anti-MUC5AC, NOE-102(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA NOE-102
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW